Form 4: Akoya Biosciences CFO Reports Full Disposition of Holdings Following Quanterix Merger Completion

Akoya Biosciences, Inc. CFO John Frederick Ek has reported the complete disposition of his beneficial ownership in Akoya common stock and stock options, effective July 8, 2025, as a result of the company's merger with Quanterix Corporation.

Summary

• John Frederick Ek, CFO of Akoya Biosciences, Inc. (AKYA), reported changes in his beneficial ownership due to the merger of Akoya Biosciences with Quanterix Corporation.
• On July 8, 2025, Akoya Biosciences became a wholly-owned subsidiary of Quanterix Corporation.
• All outstanding shares of Akoya common stock were converted into the right to receive 0.1461 shares of Quanterix common stock and $0.38 in cash per share.
• Akoya restricted stock units (RSUs) were converted into the right to receive the same per share merger consideration upon vesting.
• All outstanding options to purchase Akoya common stock were accelerated, and those with an exercise price equal to or greater than the Per Share Merger Consideration were terminated and cancelled for no consideration.
• John Ek disposed of 54,452 shares of common stock, 193,750 shares related to RSUs, and 20,000 shares held indirectly through the Ek Trust.
• He also disposed of 160,000 employee stock options with an exercise price of $7.6 and 70,000 employee stock options with an exercise price of $5.35.
• Following these transactions, John Ek holds no direct or indirect beneficial ownership in Akoya Biosciences, Inc. securities.

Sentiment

Score: 5

Explanation: The document is a factual report of a completed corporate action (merger) and its impact on an insider's holdings. It does not contain subjective language or forward-looking projections that would significantly sway sentiment, though the cancellation of some options is a negative for those specific holders.

Positives

• The merger with Quanterix Corporation has successfully closed, providing Akoya shareholders with a combination of Quanterix stock and cash.
• The merger provides a clear exit strategy for Akoya shareholders and integrates Akoya into a larger entity, potentially offering broader resources.

Negatives

• Akoya Biosciences, Inc. common stock is no longer publicly traded, as it is now a wholly-owned subsidiary of Quanterix Corporation.
• Certain employee stock options with exercise prices equal to or greater than the Per Share Merger Consideration were terminated and cancelled for no consideration, resulting in a loss for those option holders.

Risks

• The Per Share Stock Consideration and Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement, introducing potential variability in the final value received by shareholders.
• Employee stock options with exercise prices at or above the merger consideration were cancelled, indicating a potential loss for some option holders.

Future Outlook

The document reports a completed merger, indicating Akoya Biosciences will operate as a wholly-owned subsidiary of Quanterix Corporation. No specific forward-looking statements regarding future performance or strategic direction are provided for the combined entity.

Industry Context

This transaction represents a consolidation within the life sciences and biotechnology sector, specifically in the area of advanced biological analysis. The acquisition of Akoya Biosciences by Quanterix Corporation suggests a strategic move to combine capabilities or expand market reach in this specialized field.

Stakeholder Impact

• Shareholders of Akoya Biosciences: Their shares were converted into Quanterix common stock and cash, effectively ending their direct ownership in Akoya.
• Employees (specifically option holders) of Akoya Biosciences: Some employee stock options were terminated for no consideration if their exercise price was equal to or greater than the Per Share Merger Consideration, impacting their potential gains.

Next Steps

• Akoya Biosciences, Inc. will operate as a wholly-owned subsidiary of Quanterix Corporation.
• Akoya shareholders will receive the Per Share Merger Consideration (Quanterix stock and cash) for their shares.
• Akoya RSU holders will receive the Per Share Merger Consideration upon vesting of their Rollover RSUs.

Key Dates

Keywords

Akoya Biosciences, Quanterix Corporation, Merger, SEC Form 4, Insider Trading, Beneficial Ownership, Stock Options, Restricted Stock Units, Corporate Acquisition, John Frederick Ek, CFO, AKYA